Alesia A. Khan

Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Journal: HemaSphere

Published: April 27, 2026

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Journal: British journal of haematology

Published: February 25, 2026

Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.

Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.

Journal: British journal of haematology

Published: September 15, 2025

Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.

Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.

Journal: British journal of haematology

Published: April 19, 2024

Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.

Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.

Journal: American journal of hematology

Published: January 04, 2024

Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.

Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.

Journal: The Lancet. Haematology

Published: August 22, 2023

The management of myelofibrosis: A British Society for Haematology Guideline.

The management of myelofibrosis: A British Society for Haematology Guideline.

Journal: British journal of haematology

Published: August 15, 2023

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Journal: British journal of haematology

Published: August 15, 2023

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center.

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center.

Journal: HemaSphere

Published: March 17, 2021

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.

Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.

Journal: Leukemia

Published: December 12, 2018

Immunological Consequences of JAK Inhibition: Friend or Foe?

Immunological Consequences of JAK Inhibition: Friend or Foe?

Journal: Current hematologic malignancy reports

Published: August 22, 2015

Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?

Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?

Journal: British journal of haematology

Published: April 21, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026